Company profile
Dare Bioscience, Inc.
NASDAQ:DAREBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05418426 | phase1 | completed | 2020-08-18 | 2021-04-27 | Daré Bioscience, Inc. | A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women |
| NCT05752526 | phase1 | completed | 2023-05-19 | 2023-10-10 | Daré Bioscience, Inc. | A Study of Diclofenac Gel in Women With Primary Dysmenorrhea |
| NCT07601074 | phase2 | recruiting | 2026-07-17 | 2027-10-01 | Daré Bioscience, Inc. | A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) |
| NCT06668896 | phase1 | not_yet_recruiting | 2026-09-01 | 2027-11-01 | Daré Bioscience, Inc. | Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert |
| NCT04370548 | phase3 | completed | 2020-06-16 | 2020-11-30 | Daré Bioscience, Inc. | DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) |
FDA applications (0)
No records yet.